2nd Annual European Neuroscience Innovation Forum

2nd Annual European Neuroscience Innovation Forum

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

2nd of March 2027|HILTON ZURICH AIRPORT HOTEL | SWITZERLAND

We are pleased to announce the 2nd Annual European Neuroscience Innovation Forum (#Sachs_ENIF), which will take place on the 2nd of March 2027 at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week (#SSLSW), which will incorporate the 20th Annual European Life Sciences CEO Forum (#Sachs_ELSF), allowing relevant attendees to register for both events. 

Building on the success of its previous edition, the forum will provide a dedicated platform for corporate and financial investors, pharma executives, and advisors to engage with leading and emerging neuroscience companies. The forum will address drug and tech innovation in Europe and the latest global developments in CNS. For companies attending, there is an opportunity to network with the large investor audience participating in both ENIF and ELSF. 

The physical programme will feature panels and keynotes, which will be recorded and available on demand by the 11th of March. In addition, the event will feature pre-arranged in-person meetings, virtual partnering during the Online Partnering Week, and a networking reception, offering ample opportunities to engage with stakeholders across the neuroscience ecosystem. 

The target audience consists of buy and sell-side analysts from investment banks and funds, alongside partnering executives from pharma, Biotech, MedTech, Neurotech, and diagnostics companies. We anticipate 250+ delegates attending in-person and 25+ company presentations by established and emerging companies. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the Event Portal during the virtual week.  

The In-Person meetings will take place on the 2nd of March, while virtual meetings will occur on the 9th - 11th of March. For virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function, and we will have a dedicated room for in-person meetings.  

The conference will be held in the Central European Time Zone.

Panels & Sessions on the 2nd of March Include:

  • Pharma CNS Strategy Panel: Outlook for Dealmaking in 2027
  • Next Wave of Dementia Care: Multi-Target Modalities & Early Detection
  • PD & Movement Disorders Panel: Tackling the Fast-Growing Disorder
  • Overcoming Barriers in ALS & Huntington’s: Delivery, Targets & Modalities
  • Neuropsychiatry & Precision Medicine Panel: New Targets & Modalities
  • Next-Generation Neurotech: Redefining Possibilities in Brain Health
  • Investor Roundtable

In-Person Meetings:

  • 2nd of March

Online Virtual Meetings:

  • 9th - 11th of March

Reception:

  • 2nd of March

1st Annual European Neuroscience Innovation Forum — Keynote Speakers Included:

Jonathan Javitt
CEO, NRx Pharmaceuticals, Inc.
Richard Porter
Chief Business & Scientific Officer, uniQure

1st Annual European Neuroscience Innovation Forum — Chairs & Speakers Included:

Alexander Gebauer
Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc.
Andrea Chicca
Co-Founder & CEO, Synendos Therapeutics AG
Antonio Mazzeo
BD/M&A Executive Director, Angelini Pharma S.p.A.
Camille Nicoleau
Director Search & Evaluation - Neurology & Rare Diseases, Servier
Dani Bach
Managing Partner, Limani Partners
Davor Kosanic
CEO, Reconnect Labs AG
Delphine Charvin
Co-Founder & CEO, Elkedonia SAS
Diana Saraceni
Co-Founder & General Partner, Panakès Partners SGR SpA
Gabrielle Åhlberg Hillert
Chief Medical Officer, BioArctic AB
Gil Beyen
CEO, Montis Biosciences
Ivo Staijen
Head, Public Equity, HBM Partners AG
Jessica Tomé-Garcia
Lead Scientific Program Manager, The Michael J. Fox Foundation for Parkinson's Research
Josep Prous
Co-Founder & Chief Scientific Officer, CONNECTA Therapeutics, S.L.
Jyothis George
Chief Medical Officer, NodThera, Inc.
Karen Wagner
Managing Partner, Ysios Capital
Kathy Xiang
VP Business & Corporate Development, Compass Pathways
Kirsten Scott
Clinical Lead, AC Immune
Klaus Dugi
CEO, Vandria SA
Laurent Richebourg
CEO, Curlim
Lynsey Bilsland
Managing Director, Parkinson's Research Ventures Ltd
Marc Dechamps
CEO, Bioxodes SA
Megan McGill
CEO, Brenig Therapeutics
Michael Salzmann
CEO, AL-S Pharma AG
Nicki Thompson
CEO, TRIMTECH Therapeutics
Per Lundin
Co-Founder & CEO, Evox Therapeutics Ltd.
Richard Munton
Senior Business Development Director, F. Hoffmann-La Roche
Richard Porter
Chief Business & Scientific Officer, uniQure
Sahil Kirpekar
Managing Partner, Lumina Life Sciences
Sara Secall
Partner, Inveready Asset Management
Torsten Madsen
CEO, IAMA Therapeutics S.r.l.
Willem Broekaert
Managing Partner, V-Bio Ventures BV

1st Annual European Neuroscience Innovation Forum — Presenting Companies Included:

Amporin Pharmaceuticals AG logo
Amyl Therapeutics SRL logo
Aprecia Pharmaceuticals logo
Bioxodes SA logo
Curlim logo
Elkedonia SAS logo
Evox Therapeutics Ltd. logo
Galimedix Therapeutics, Inc. logo
IAMA Therapeutics S.r.l. logo
Macomics Ltd. logo
Reconnect Labs AG logo
SpliceBio, S.L logo
Vandria SA logo

Previous Highlights:

2nd Annual European Neuroscience Innovation Forum event highlight
2nd Annual European Neuroscience Innovation Forum event highlight
2nd Annual European Neuroscience Innovation Forum event highlight
2nd Annual European Neuroscience Innovation Forum event highlight
2nd Annual European Neuroscience Innovation Forum event highlight

To learn more about presenting, exhibiting or sponsorship opportunities, please contact us at SachsTeam@SachsForum.com or call us on + 44 203 463 4890.